Mallinckrodt (Mallinckrodt) Research & Development : $113 Mil (TTM As of Sep. 2023)

View and export this data going back to 2002. Start your Free Trial

What is Mallinckrodt Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Mallinckrodt's Research & Development for the three months ended in Sep. 2023 was $26 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2023 was $113 Mil.

Mallinckrodt Research & Development Historical Data

The historical data trend for Mallinckrodt's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mallinckrodt Research & Development Chart

Mallinckrodt Annual Data

Trend

Sep13

Sep14

Sep15

Sep16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Research & Development

Get a 7-Day Free Trial

361.10

349.40

290.80

205.20

Mallinckrodt Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Research & Development	Get a 7-Day Free Trial															34.50	29.70	28.30	29.00	25.70

Mallinckrodt Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $113 Mil.

Mallinckrodt (OTCPK:MNKKQ) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Mallinckrodt Research & Development Related Terms

Thank you for viewing the detailed overview of Mallinckrodt's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Mallinckrodt (Mallinckrodt) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mallinckrodt PLC (OTCPK:MNKKQ) » Definitions » Research & Development

Comparable Companies

Traded in Other Exchanges

N/A

Address

College Business and Technology Park, Cruiserath, Blanchardstown, Dublin, IRL, 15

Website

https://www.mallinckrodt.com

Mallinckrodt PLC develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies. Its areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. The company operates its business in two reportable segments namely Specialty Brands which include specialty pharmaceutical brands; and Specialty Generics which includes niche specialty generic drugs and active pharmaceutical ingredients. It generates maximum revenue from the Specialty Brands segment. Geographically, it derives a majority of its revenue from the United States.

Executives

Sigurdur O Olafsson	director, officer: President and CEO	360 MOUNT KEMBLE AVENUE, MORRISTOWN NJ 07960
Myers Woodrow A Jr	director	1 N ILLINOIS SREET 2101, INDIANAPOLIS IN 46204
Fyi S.a R.l.	10 percent owner	19, RUE DE BITBOURG, LUXEMBOURG N4 L-1273
Ffi Iii S.a R.l.	10 percent owner	19, RUE DE BITBOURG, LUXEMBOURG N4 L-1273
Olifant Luxco S.a R.l.	10 percent owner	19, RUE DE BITBOURG, LUXEMBOURG N4 L-1273
Daniel Arthur Celentano	director	2831 S. BAYSHORE DRIVE, UNIT 2103, MIAMI FL 33133
Riad Hussein El-dada	director	910 TALAMORE DRIVE, AMBLER PA 19002
Bracebridge Capital, Llc	10 percent owner	888 BOYLSTON STREET, SUITE 1500, BOSTON MA 02199
Kassie Harrold	officer: Chief Compliance Officer	C/O MALLINCKRODT PHARMACEUTICALS, 675 MCDONNELL BLVD., HAZELWOOD MO 63042
Neal P Goldman	director	10700 PARKRIDGE BLVD., RESTON VA 20191
Steven J. Romano	officer: EVP & Chief Sci. Ofcr	675 MCDONNELL BLVD., HAZELWOOD MO 63042
David Y Norton	director	8 GREENHOLM STREET, APT C, PRINCETON NJ 08540
Carlos V Paya	director	C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E, SUITE 310, SEATTLE WA 98102
Anne Clem Whitaker	director	109 BRIERY BRANCH COURT, MORRISVILLE NC 27560
James R Sulat	director